Warfarin Time in Therapeutic INR Range and Direct Oral Anticoagulant Adherence for Venous Thromboembolism Across the Spectrum of Weight and Body Mass Index: Findings from Veterans Health Administration

Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation

(2021) Karlyn A. Martin et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Practice Variation in Anticoagulation Prescription and Outcomes after Device-Detected Atrial Fibrillation: Insights from the Veterans Health Administration

(2019) Alexander C. Perino et al.   CIRCULATION

Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data

(2019) Margarita Kushnir et al.   Lancet Haematology

Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation

(2018) Kazuhiko Kido et al.   ANNALS OF PHARMACOTHERAPY

Real-world adherence to oral anticoagulants in atrial fibrillation patients: a study protocol for a systematic review and meta-analysis

(2018) Clara L Rodríguez-Bernal et al.   BMJ Open

Bleeding complications and mortality in warfarin-treated VTE patients, dependence of INR variability and iTTR

(2017) Henrik Renlund et al.   THROMBOSIS AND HAEMOSTASIS

The ‘obesity paradox’ in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial

(2016) Roopinder K. Sandhu et al.   EUROPEAN HEART JOURNAL

Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH

(2016) K. Martin et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Site-Level Variation in and Practices Associated With Dabigatran Adherence

(2015) Supriya Shore et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Warfarin Dosing and Body Mass Index

(2014) Julia A. Mueller et al.   ANNALS OF PHARMACOTHERAPY

National Assessment of Warfarin Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation

(2014) Jeffrey S. Dlott et al.   CIRCULATION

Increased Mortality Associated With Digoxin in Contemporary Patients With Atrial Fibrillation

(2014) Mintu P. Turakhia et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Antiobesity medication use across the veterans health administration: Patient-level predictors of receipt

(2014) A. C. Del Re et al.   Obesity

Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects

(2013) Vijay V. Upreti et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients

(2013) Paul A. Reilly et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: The Retrospective Evaluation and Assessment of Therapies in AF (TREAT-AF) study

(2012) Mintu P. Turakhia et al.   AMERICAN HEART JOURNAL

Benchmark for Time in Therapeutic Range in Venous Thromboembolism: A Systematic Review and Meta-Analysis

(2012) Petra M. G. Erkens et al.   PLoS One

VHA Corporate Data Warehouse height and weight data: Opportunities and challenges for health services research

(2010) Polly Hitchcock Nol et al.   JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT

Oral Rivaroxaban for Symptomatic Venous Thromboembolism

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range

(2008) Stuart J. Connolly et al.   CIRCULATION